YH YOUHEALTH AB

Their core work

YouHealth AB is a Swedish digital health SME that brings real-world patient data capabilities and health informatics infrastructure to large European research consortia. Their work supports multiomics-driven disease research — integrating genomic, epigenomic, and immunological data to identify biomarkers and disease mechanisms in complex conditions. In practice, they function as a data and patient engagement platform provider within academic-led consortia studying diseases where lifestyle, genetics, and immune dysfunction intersect. Their participation in both a neurological immune disease programme (MultipleMS) and a liver disease systems biology project (DECISION) suggests their core platform is disease-agnostic, built around longitudinal patient data collection and multiomics integration.

What they specialise in

How they've shifted over time

In their first H2020 project (from 2017), YouHealth worked squarely in neurological immune disease — multiple sclerosis characterised through genetics, epigenetics, lifestyle exposures, and immunophenotyping, with a strong emphasis on patient heterogeneity. By 2020, their focus shifted to hepatology: decompensated cirrhosis, survival prediction, infection, and combinatorial therapy identification using systems-level omics approaches. The underlying methodological thread — multiomics, data integration, complex disease mechanisms — is consistent, but the disease domain has broadened from neuroimmunology to liver disease, suggesting their platform and analytical capabilities transfer across disease areas rather than being tied to a single therapeutic field.

YouHealth is building cross-disease expertise in data-driven precision medicine — their trajectory points toward becoming a versatile multiomics data platform for rare and complex diseases beyond their initial MS focus.

How they like to work

YouHealth has participated exclusively as a consortium partner — never as a coordinator — across both of their H2020 projects, indicating a deliberate specialist-contributor model rather than project leadership ambitions. Despite only two projects, they have engaged with 46 unique partners across 13 countries, which points to involvement in large, multi-partner RIA consortia typical of EU health research networks. This suggests they are comfortable operating within complex collaborative structures and bring a specific, well-defined contribution — likely data infrastructure or patient platform capabilities — rather than serving as a generalist research partner.

YouHealth has built a notably wide network for a two-project SME — 46 unique partners in 13 countries — driven by their participation in large research consortia such as MultipleMS, which typically involve dozens of academic and clinical institutions across Europe. Their network is European in scope with no obvious single-country concentration.

What sets them apart

YouHealth is one of very few Swedish private SMEs active in H2020 health research consortia at the multiomics and systems biology level — a space dominated by universities and research institutes. Their value proposition is the rare combination of a patient-facing digital health platform with the technical depth to contribute meaningfully to omics-driven academic research. For consortium builders, they offer something that pure academic partners cannot: the operational infrastructure to collect real-world patient data, lifestyle exposures, and longitudinal health information at scale, packaged within an SME that moves faster than a hospital and is eligible for SME-specific EU funding instruments.

Highlights from their portfolio

• MultipleMS
  The largest investment in YouHealth's portfolio (EUR 1.25M, running 2017-2023), this flagship project placed them at the centre of one of Europe's most comprehensive multiomics studies of multiple sclerosis heterogeneity.
• DECISION
  Running to 2026, this project marks YouHealth's expansion into liver disease and systems biology — signalling capability transfer beyond their original neuroimmunology context and into combinatorial therapy identification for a high-mortality condition.